Determination of Isavuconazole Susceptibility of Aspergillus and Candida Species by the EUCAST Method
Open Access
- 1 November 2013
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (11) , 5426-5431
Abstract
Isavuconazole is a novel expanded-spectrum triazole, which has recently been approved by the FDA as an orphan drug to treat invasive aspergillosis and is currently being studied in phase III clinical trials for invasive candidiasis. The susceptibility of relatively few clinical isolates has been reported. In this study, the isavuconazole susceptibilities of 1,237 Aspergillus and 2,010 Candida geographically diverse clinical isolates were determined by EUCAST methodology at four European mycology laboratories, producing the largest multicenter data set thus far for this compound. In addition, a blinded collection of 30 cyp51A mutant Aspergillus fumigatus clinical isolates and 10 wild-type isolates was tested. From these two data sets, the following preliminary epidemiological cutoff (ECOFF) values were suggested: 2 mg/liter for Aspergillus fumigatus , Aspergillus terreus , and Aspergillus flavus ; 4 mg/liter for Aspergillus niger ; 0.25 mg/liter for Aspergillus nidulans ; and 0.03 mg/liter for Candida albicans , Candida parapsilosis , and Candida tropicalis . Unfortunately, ECOFFs could not be determined for Candida glabrata or Candida krusei due to an unexplained interlaboratory MIC variation. For the blinded collection of A. fumigatus isolates, all MICs were ≤2 mg/liter for wild-type isolates. Differential isavuconazole MICs were observed for triazole-resistant A. fumigatus isolates with different cyp51A alterations: TR 34 /L98H mutants had elevated isavuconazole MICs, whereas isolates with G54 and M220 alterations had MICs in the wild-type range, suggesting that the efficacy of isavuconazole may not be affected by these alterations. This study will be an aid in interpreting isavuconazole MICs for clinical care and an important step in the future process of setting official clinical breakpoints.Keywords
This publication has 21 references indexed in Scilit:
- Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral SuspensionAntimicrobial Agents and Chemotherapy, 2012
- In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility TestingDiagnostic Microbiology and Infectious Disease, 2011
- Voriconazole Pharmacokinetics and Pharmacodynamics in ChildrenClinical Infectious Diseases, 2010
- Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory ExperienceAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2009
- Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2009
- Antifungal Therapeutic Drug Monitoring: Established and Emerging IndicationsAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium SpeciesAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream IsolatesAntimicrobial Agents and Chemotherapy, 2007